Comparative Pharmacology
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE versus NEPTAZANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE versus NEPTAZANE.
DORZOLAMIDE HYDROCHLORIDE vs NEPTAZANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
Methazolamide is a carbonic anhydrase inhibitor. It decreases intraocular pressure by inhibiting carbonic anhydrase in the ciliary epithelium, reducing aqueous humor secretion. It also has weak diuretic effects due to renal carbonic anhydrase inhibition.
One drop of 2% solution in the affected eye(s) three times daily.
50 mg orally twice daily, increasing to 50 mg three times daily if needed. Maximum dose: 200 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Terminal elimination half-life: 8-12 hours. In renal impairment, half-life may extend to 20-30 hours, requiring dose adjustment.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Renal: 100% as unchanged drug via tubular secretion. No biliary or fecal elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor